The Latest Breaking News from Medicines and Healthcare products Regulatory Agency

Popular cold and flu medicines could be banned over 'links to brain disorders'

Health officials are examining evidence on whether distribution rules of some of the most common cold medicines need to change.

Daily Record · Feb 23, 2023

Most commonly used cold and flu medicines in the country could be banned

Health experts in the UK and Europe are looking into links between the over-the-counter drugs and serious health conditions

Wales Online · Feb 23, 2023

Sudafed, Nurofen cold & flu and Day Nurse could be BANNED over brain disorder links

Medical chiefs in the UK and Europe have launched a review of medicines like Sudafed and Nurofen cold & flu over concerns of one of the ingredients which could cause two rare brain conditions

Daily Mirror · Feb 22, 2023

Urgent warning for people who take antibiotic due to contamination fears

At least four people fell ill within hours being given a dose from one of the affected batches

Liverpool Echo · Oct 24, 2022

Woman killed by herbal remedies she took to treat arthritis

A north London woman suffered liver failure and died after she was given herbal remedies to try to treat her arthritis, an inquest has found.

Evening Standard · Sep 28, 2022

HRT medication can now be bought over the counter at highstreet pharmacy

Boots pharmacies are selling the drug Gina - a low-dose hormone replacement therapy aimed at post-menopausal women - following a landmark ruling by the Medicines and Healthcare products Regulatory Agency

Daily Mirror · Sep 7, 2022

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga · Aug 26, 2022

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga · Aug 15, 2022

'Next generation' dual-strain Covid-19 vaccine approved in UK

A “next generation” Covid-19 booster jab which is the first to target two strains of the virus has been approved for use in adults in the UK.The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Moderna’s bivalent vaccine, which targets both the original Covid strain and the Omicron variant.Known…

Evening Standard · Aug 15, 2022

'Next generation' Covid jab approved in UK for use in adults

A new coronavirus booster jab has been approved for use in adults.

The National (Scotland) · Aug 15, 2022